English (UK)
中文版Innovation center of high performance medical device 
IHM-GBA is an investor and an innovation center in Guangzhou, China. The firm is looking to invest in the medical device sector. The firm is highly focusing on investment and cooperation in high-performance innovative medical device companies. The firm also helps companies to enter the Chinese market.
Steve Wu
Bd directorInnovation Centre Denmark Shanghai
Partnership between Ministry of Foreign Affair and Ministry of Higher Education and Science of Denmark. Help danish high-tech companies and research instututes to enter Chinese market and find Chinese collaborators
昱 祁
创新合作官员IQVIA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research.
竹芸 郭
Senior consultantjanssen
Xi 'an Janssen Pharmaceutical Co., Ltd. is the largest pharmaceutical joint venture in China and the largest subsidiary of Johnson & Johnson in China. Founded in 1985, the company is headquartered in Beijing, with its production base located in Xi 'an and over 3,000 employees. The company's business includes the production and sale of high quality pharmaceuticals, mainly in the fields of gastroenterology, neuropsychiatry, allergy, pain management, anti-infection, biological agents and oncology.
鑫鑫 闵
医学教育经理
Jemincare
Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.
Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.
Mrs. Lilian Peng
BD ManagerJiangbei New area
JIANGBEI NEW AREA IS THE 13rd national new area，and 1st in jiangsu province.
Qin Liu
managerJiangsu Hengrui Medicine Co.,Ltd.
Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Responsive Web Design powered by 